Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins

Marcos J. Guerrero-Muñoz, Diana L. Castillo-Carranza, Rakez Kayed

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Impaired proteostasis is one of the main features of all amyloid diseases, which are associated with the formation of insoluble aggregates from amyloidogenic proteins. The aggregation process can be caused by overproduction or poor clearance of these proteins. However, numerous reports suggest that amyloid oligomers are the most toxic species, rather than insoluble fibrillar material, in Alzheimer's, Parkinson's, and Prion diseases, among others. Although the exact protein that aggregates varies between amyloid disorders, they all share common structural features that can be used as therapeutic targets. In this review, we focus on therapeutic approaches against shared features of toxic oligomeric structures and future directions.

Original languageEnglish (US)
Pages (from-to)468-478
Number of pages11
JournalBiochemical Pharmacology
Volume88
Issue number4
DOIs
StatePublished - Apr 15 2014

Fingerprint

Amyloidogenic Proteins
Poisons
Oligomers
Amyloid
Prion Diseases
Prions
Parkinson Disease
Alzheimer Disease
Therapeutics
Agglomeration
Proteins

Keywords

  • Amyloid oligomers
  • Anti-amyloid small molecules
  • Immunotherapy

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry

Cite this

Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins. / Guerrero-Muñoz, Marcos J.; Castillo-Carranza, Diana L.; Kayed, Rakez.

In: Biochemical Pharmacology, Vol. 88, No. 4, 15.04.2014, p. 468-478.

Research output: Contribution to journalArticle

@article{ca59fc9b6638419d88bad06d25245e9c,
title = "Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins",
abstract = "Impaired proteostasis is one of the main features of all amyloid diseases, which are associated with the formation of insoluble aggregates from amyloidogenic proteins. The aggregation process can be caused by overproduction or poor clearance of these proteins. However, numerous reports suggest that amyloid oligomers are the most toxic species, rather than insoluble fibrillar material, in Alzheimer's, Parkinson's, and Prion diseases, among others. Although the exact protein that aggregates varies between amyloid disorders, they all share common structural features that can be used as therapeutic targets. In this review, we focus on therapeutic approaches against shared features of toxic oligomeric structures and future directions.",
keywords = "Amyloid oligomers, Anti-amyloid small molecules, Immunotherapy",
author = "Guerrero-Mu{\~n}oz, {Marcos J.} and Castillo-Carranza, {Diana L.} and Rakez Kayed",
year = "2014",
month = "4",
day = "15",
doi = "10.1016/j.bcp.2013.12.023",
language = "English (US)",
volume = "88",
pages = "468--478",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins

AU - Guerrero-Muñoz, Marcos J.

AU - Castillo-Carranza, Diana L.

AU - Kayed, Rakez

PY - 2014/4/15

Y1 - 2014/4/15

N2 - Impaired proteostasis is one of the main features of all amyloid diseases, which are associated with the formation of insoluble aggregates from amyloidogenic proteins. The aggregation process can be caused by overproduction or poor clearance of these proteins. However, numerous reports suggest that amyloid oligomers are the most toxic species, rather than insoluble fibrillar material, in Alzheimer's, Parkinson's, and Prion diseases, among others. Although the exact protein that aggregates varies between amyloid disorders, they all share common structural features that can be used as therapeutic targets. In this review, we focus on therapeutic approaches against shared features of toxic oligomeric structures and future directions.

AB - Impaired proteostasis is one of the main features of all amyloid diseases, which are associated with the formation of insoluble aggregates from amyloidogenic proteins. The aggregation process can be caused by overproduction or poor clearance of these proteins. However, numerous reports suggest that amyloid oligomers are the most toxic species, rather than insoluble fibrillar material, in Alzheimer's, Parkinson's, and Prion diseases, among others. Although the exact protein that aggregates varies between amyloid disorders, they all share common structural features that can be used as therapeutic targets. In this review, we focus on therapeutic approaches against shared features of toxic oligomeric structures and future directions.

KW - Amyloid oligomers

KW - Anti-amyloid small molecules

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=84897954120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897954120&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2013.12.023

DO - 10.1016/j.bcp.2013.12.023

M3 - Article

VL - 88

SP - 468

EP - 478

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 4

ER -